Key facts
- AiRato’s last known valuation is $14.9M (Jun 2025).
- It has raised $5.1M; the latest was Early Stage VC ($4.4M) in Jun 2025.
- Notable investors include SMBC Venture Capital, Nissay Capital, Intellectual Property Acceleration Program for Startups, Mirai Cross, Mint (Japan) — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for AiRato
- ·The full record, as it builds
Funding rounds
No funding rounds for AiRato are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AiRato
Developer of radiotherapy AI technology designed to enhance the effectiveness and efficiency of advanced radiation treatments. The company's platform utilizes artificial intelligence trained on clinical data from domestic centers to automate key processes in intensity-modulated radiation therapy, enabling cancer patients to access precise and less physically taxing treatments while supporting clinicians in delivering improved therapeutic outcomes with reduced operational workload.
- Sector
- Healthcare
- HQ
- Sendai, Japan
- Employees
- 10
- Website
- airato.jp/
- Ownership
- Privately Held (backing)
AiRato doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AiRato shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AiRato in its N-PORT filings yet. We sweep new filings monthly.